Simultaneous in-field boost for patients with 1 to 4 brain metastasis/es treated with volumetric modulated arc therapy: A prospective study on quality-of-life

Radiation Oncology

Volumn 6, Issue 1, 2011, Pages

  Weber, Damien C ^a,b   Caparrotti, Francesca ^a   Laouiti, Mohamed ^a   Malek, Karim ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ALOPECIA; ARTICLE; BLADDER FUNCTION; BRAIN DYSFUNCTION; BRAIN METASTASIS; BRAIN SIZE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANCER SURVIVOR; CLINICAL ARTICLE; EMOTION; ERYTHEMA; FEMALE; FOLLOW UP; HEADACHE; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MALE; PHYSICAL ACTIVITY; QUALITY OF LIFE; QUESTIONNAIRE; RADIATION DOSE FRACTIONATION; RADIATION INJURY; SELF EVALUATION; SIMULTANEOUS IN FIELD BOOST; SKIN TOXICITY; TUMOR GROWTH; VOLUMETRIC MODULATED ARC THERAPY; BRAIN; BRAIN TUMOR; HEALTH STATUS; METASTASIS; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; TREATMENT OUTCOME;

AGED; BRAIN; BRAIN NEOPLASMS; FEMALE; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; RADIOTHERAPY, INTENSITY-MODULATED; TREATMENT OUTCOME;

EID: 79959651037     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-6-79     Document Type: Article

References (30)

1. Nussbaum ES, Djalilian HR, Cho KH, Hall WA. Brain metastases. Histology, multiplicity, surgery, and survival. Cancer 1996, 78(8):1781-8. 10.1002/(SICI)1097-0142(19961015)78:8<1781::AID-CNCR19>3.0.CO;2-U, 8859192.
2. Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 2004, 363(9422):1665-72. 10.1016/S0140-6736(04)16250-8, 15158627.
3. Kondziolka D, Patel A, Lunsford LD, Kassam A, Flickinger JC. Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. International journal of radiation oncology, biology, physics 1999, 45(2):427-34. 10.1016/S0360-3016(99)00198-4, 10487566.
4. Meyers CA, Smith JA, Bezjak A, Mehta MP, Liebmann J, Illidge T, et al. Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. J Clin Oncol 2004, 22(1):157-65.
5. Li J, Bentzen SM, Li J, Renschler M, Mehta MP. Relationship between neurocognitive function and quality of life after whole-brain radiotherapy in patients with brain metastasis. International journal of radiation oncology, biology, physics 2008, 71(1):64-70. 10.1016/j.ijrobp.2007.09.059, 18406884.
6. Casanova N, Mazouni Z, Bieri S, Combescure C, Pica A, Weber DC. Whole brain radiotherapy with a conformational external beam radiation boost for lung cancer patients with 1-3 brain metastasis: a multi institutional study. Radiat Oncol 2010, 5:13. 10.1186/1748-717X-5-13, 2834695, 20167107.
7. Harwood AR, Simson WJ. Radiation therapy of cerebral metastases: a randomized prospective clinical trial. International journal of radiation oncology, biology, physics 1977, 2(11-12):1091-4. 10.1016/0360-3016(77)90114-6, 74375.
8. Borgelt B, Gelber R, Kramer S, Brady LW, Chang CH, Davis LW, et al. The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. International journal of radiation oncology, biology, physics 6(1):1-9.
9. Sehlen S, Lenk M, Hollenhorst H, Schymura B, Aydemir U, Herschbach P, et al. Quality of life (QoL) as predictive mediator variable for survival in patients with intracerebral neoplasma during radiotherapy. Onkologie 2003, 26(1):38-43. 10.1159/000069862, 12624516.
10. Regine WF, Schmitt FA, Scott CB, Dearth C, Patchell RA, Nichols RC, et al. Feasibility of neurocognitive outcome evaluations in patients with brain metastases in a multi-institutional cooperative group setting: results of Radiation Therapy Oncology Group trial BR-0018. International journal of radiation oncology, biology, physics 2004, 58(5):1346-52. 10.1016/j.ijrobp.2003.09.023, 15050309.
11. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993, 85(5):365-76. 10.1093/jnci/85.5.365, 8433390.
12. Osoba D, Aaronson NK, Muller M, Sneeuw K, Hsu MA, Yung WK, et al. The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires. Qual Life Res 1996, 5(1):139-50. 10.1007/BF00435979, 8901377.
13. Taphoorn MJ, Claassens L, Aaronson NK, Coens C, Mauer M, Osoba D, et al. An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients. Eur J Cancer 2010, 46(6):1033-40. 10.1016/j.ejca.2010.01.012, 20181476.
14. Komosinska K, Kepka L, Niwinska A, Pietrzak L, Wierzchowski M, Tyc-Szczepaniak D, et al. Prospective evaluation of the palliative effect of whole-brain radiotherapy in patients with brain metastases and poor performance status. Acta oncologica (Stockholm, Sweden) 2010, 49(3):382-8.
15. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975, 12(3):189-98. 10.1016/0022-3956(75)90026-6, 1202204.
16. Murray KJ, Scott C, Zachariah B, Michalski JM, Demas W, Vora NL, et al. Importance of the mini-mental status examination in the treatment of patients with brain metastases: a report from the Radiation Therapy Oncology Group protocol 91-04. International journal of radiation oncology, biology, physics 2000, 48(1):59-64. 10.1016/S0360-3016(00)00600-3, 10924972.
17. Kaplan E, Meier P. Nonparametric estimation for incomplete observations. J Am Stat Assoc 53:458-481.
18. Steinmann D, Schafer C, van Oorschot B, Wypior HJ, Bruns F, Bolling T, et al. Effects of radiotherapy for brain metastases on quality of life (QoL). Prospective pilot study of the DEGRO QoL working party. Strahlenther Onkol 2009, 185(3):190-7. 10.1007/s00066-009-1904-0, 19330297.
19. Vordermark D. Avoiding bias in the prospective evaluation of patients with brain metastases. J Clin Oncol 2007, 25(25):4023. author reply 4024-5, 10.1200/JCO.2007.12.4610, 17761992.
20. Fromme EK, Eilers KM, Mori M, Hsieh YC, Beer TM. How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30. J Clin Oncol 22(17):3485-90.
21. Basch E, Iasonos A, McDonough T, Barz A, Culkin A, Kris MG, et al. Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. Lancet Oncol 2006, 7(11):903-9. 10.1016/S1470-2045(06)70910-X, 17081915.
22. Mauer M, Stupp R, Taphoorn MJ, Coens C, Osoba D, Marosi C, et al. The prognostic value of health-related quality-of-life data in predicting survival in glioblastoma cancer patients: results from an international randomised phase III EORTC Brain Tumour and Radiation Oncology Groups, and NCIC Clinical Trials Group study. British journal of cancer 2007, 97(3):302-7. 10.1038/sj.bjc.6603876, 2360328, 17609661.
23. Mauer ME, Taphoorn MJ, Bottomley A, Coens C, Efficace F, Sanson M, et al. Prognostic value of health-related quality-of-life data in predicting survival in patients with anaplastic oligodendrogliomas, from a phase III EORTC brain cancer group study. J Clin Oncol 2007, 25(36):5731-7. 10.1200/JCO.2007.11.1476, 18089867.
24. Meyers CA, Hess KR, Yung WK, Levin VA. Cognitive function as a predictor of survival in patients with recurrent malignant glioma. J Clin Oncol 18(3):646-50.
25. Klein M, Postma TJ, Taphoorn MJ, Aaronson NK, Vandertop WP, Muller M, et al. The prognostic value of cognitive functioning in the survival of patients with high-grade glioma. Neurology 2003, 61(12):1796-8.
26. Rodrigues G, Yartsev S, Yaremko B, Perera F, Dar AR, Hammond A, et al. Phase I Trial of Simultaneous In-Field Boost With Helical Tomotherapy for Patients With One to Three Brain Metastases. International journal of radiation oncology, biology, physics 2010,
27. Bauman G, Yartsev S, Fisher B, Kron T, Laperriere N, Heydarian M, et al. Simultaneous infield boost with helical tomotherapy for patients with 1 to 3 brain metastases. American journal of clinical oncology 2007, 30(1):38-44. 10.1097/01.coc.0000245473.41035.c4, 17278893.
28. Lagerwaard FJ, van der Hoorn EA, Verbakel WF, Haasbeek CJ, Slotman BJ, Senan S. Whole-brain radiotherapy with simultaneous integrated boost to multiple brain metastases using volumetric modulated arc therapy. International journal of radiation oncology, biology, physics 2009, 75(1):253-9. 10.1016/j.ijrobp.2009.03.029, 19577856.
29. Patchell RA, Tibbs PA, Walsh JW, Dempsey RJ, Maruyama Y, Kryscio RJ, et al. A randomized trial of surgery in the treatment of single metastases to the brain. The New England journal of medicine 1990, 322(8):494-500. 10.1056/NEJM199002223220802, 2405271.
30. Noordijk EM, Vecht CJ, Haaxma-Reiche H, Padberg GW, Voormolen JH, Hoekstra FH, et al. The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age. International journal of radiation oncology, biology, physics 1994, 29(4):711-7. 10.1016/0360-3016(94)90558-4, 8040016.